Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system

British Journal of Haematology

Volumn 122, Issue 6, 2003, Pages 958-965

  Zorio, Esther ^a   Castelló, Remedios ^a   Falcó, Cristina ^a   España, Francisco ^a   Osa, Ana ^a   Almenar, Luis ^a   Aznar, Justo ^a   Estellés, Amparo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Fibrinolysis; Myocardial infarction; Protein C; TAFI polymorphism; Thrombin activatable fibrinolysis inhibitor (TAFI)

Indexed keywords

ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION;

ADULT; BLOOD COAGULATION; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROTEIN C;

EID: 0141540528     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04549.x     Document Type: Article

References (39)

1. Aznar, J. & Estellés, A. (1994) Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery disease. Haemostasis, 24, 243-251.
2. Aznar, J., Estellés, A., Tormo, G., Sapena, P., Tormo, V., Blanch, S. & España, F. (1988) Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. British Heart Journal, 59, 535-541.
3. Aznar, J., Estellés, A., Breté, M., España, F. & Alós, T. (1992) Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein(a). Thrombosis Research, 66, 569-582.
4. Bajzar, L. (2000) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 2511-2518.
5. Bajzar, L., Manuel, R. & Nesheim, M.E. (1995) Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. Journal of Biological Chemistry, 270, 14477-14484.
6. Bajzar, L., Nesheim, M.E. & Tracy, P.B. (1996a) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood, 88, 2093-2100.
7. Bajzar, L., Morser, J. & Nesheim, M. (1996b) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. Journal of Biological Chemistry, 271, 16603-16608.
8. Brouwers, G.J., Vos, H.L., Leebeek, F.W.G., Bulk, S., Schneider, M., Boffa, M., Koschinsky, M., van Tilburg, N.H., Nesheim, M.E., Bertina, R.M. & Gomez Garcia, E.B. (2001) A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 98, 1992-1993.
9. Eaton, D.L., Malloy, B.E., Tsai, S.P., Henzel, W. & Drayna, D. (1991) Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. Journal of Biological Chemistry, 266, 21833-21838.
10. España, F. & Griffin, J.H. (1989) Determination of functional and antigen protein C inhibitor and its complexes with activated protein C in plasma by ELISAs. Thrombosis Research, 55, 671-682.
11. España, F., Estellés, A., Aznar, J. & Gilabert, J. (1986) Assay of protein C in human plasma: comparison of amidolytic, coagulation and immunochemical assays. Thrombosis Research, 44, 771-782.
12. España, F., Zorio, E., Medina, P., Palencia, M.A., Estellés, A., Osa, A., Rodríguez, S. & Aznar, J. (2002) Low levels of circulating activated protein C are a risk factor for myocardial infarction. Pathophysiology of Haemostasis and Thrombosis, 32, 61.
13. Estellés, A., Gilabert, J., Aznar, J., Loskutoff, D.J. & Schieef, R.R. (1989) Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood, 74, 1332-1338.
14. Falcó, C., Tormo, G., Estellés, A., España, F., Tormo, E., Gilabert, J., Velasco, J.A. & Aznar, J. (2001) Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica, 86, 92-98.
15. Franco, R.F., Fagundes, M.G., Meijers, J.C., Reitsma, P.H., Lourenco, D., Morelli, V., Maffei, F.H., Ferrari, I.C., Piccinato, C.E., Silva, Jr, W.A. & Zago, M.A. (2001) Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica, 86, 510-517.
16. Gils, A., Alessi, M.C., Brouwers, E., Peeters, M., Marx, P., Leurs, J., Bouma, B., Hendriks, D., Juhan-Vague, I. & Declerck, P.J. (2003) Development of a genotype 325-specific proCPU/TAFI ELISA. Arteriosclerosis, Thrombosis, and Vascular Biology, 23 (available on line at http://www.atvbaha.org).
17. Grancha, S., Estellés, A., Tormo, G., Falcó, C., Gilabert, J., España, F., Cano, A., Seguí, R. & Aznar, J. (1999) Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Influence of hormone replacement therapy. Thrombosis and Haemostasis, 81, 516-521.
18. Henry, M., Tregouet, D.A., Alessi, M.C., Aillaud, M.F., Visvikis, S., Siest, G., Tiret, L. & Juhan-Vague, I. (1998) Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of Stanislas Cohort. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 84-91.
19. Henry, M., Aubert, H., Morange, P.E., Nanni, I., Alessi, M.C., Tiret, L. & Juhan-Vague. I. (2001) Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 97, 2053-2058.
20. Hori, Y., Gabazza, E.C., Yano, Y., Katsuki, A., Suzuki, K., Adachi, Y. & Sumida, Y. (2002) Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism, 87, 660-665.
21. Juhan-Vague, I., Renucci, J.F., Grimaux, M., Morange, P.E., Gouvernet, J., Gourmelin, Y. & Alessi, M.C. (2000) Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2156-2161.
22. Juhan-Vague, I., Morange, P.E., Aubert, H., Henry, M., Aillaud, M.F., Alessi, M.C., Samnegard, A., Hawe, E., Yudkin, J., Margaglione, M., Di Minno, G., Hamsten, A. & Humphries, S.E. (2002) Plasma Thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 867-873.
23. Marx, P.F., Dawson, P.E., Bouma, B.N. & Meijers, J.C. (2002) Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry, 41, 6688-6696.
24. Meade, T.W., Ruddock, V., Stirling, Y., Chakrabarti, R. & Miller, G.J. (1993) Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet, 342, 1076-1079.
25. Minnema, M.C., Friederich, P.W., von Levi, M., dem Borne, P.A., Mosnier, L.O., Meijers, J.C., Biemond, B.J., Hack, C.E., Bouma, B.N. & ten Cate, H. (1998) Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. Journal of Clinical Investigation, 101, 10-14.
26. Morange, P.E., Henry, M., Frere, C. & Juhan-Vague, I. (2002) Thr325Ile polymorphism of the TAFI gene does not influence the risk of myocardial infarction. Blood, 99, 1878-1879.
27. Morange, P.E., Juhan-Vague, I., Scarabin, P.Y., Alessi, M.C., Luc, G., Arveiler, D., Ferrieres, J., Amouyel, P., Evans, A. & Ducimetiere, P. (2003) Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thrombosis and Haemostasis, 89, 554-560.
28. Mosnier, L.O., Elisen, M.G., Bouma, B.N. & Meijers, J.C. (2001a) Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation. Thrombosis and Haemostasis, 86, 1057-1064.
29. Mosnier, L.O., Meijers, J.C. & Bouma, B.N. (2001b) Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thrombosis and Haemostasis, 85, 5-11.
30. Nagashima, M., Werner, M., Wang, M., Zhao, L., Light, D.R., Pagila, R., Morser, J. & Verhallen, P. (2000) An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thrombosis Research, 98, 333-342.
31. Nesheim, M., Wang, W., Boffa, M., Nagashima, M., Morser, J. & Bajzar, L. (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thrombosis and Haemostasis, 78, 386-391.
32. Redlitz, A., Nicolini, F.A., Malycky, J.L., Topol, E.J. & Plow, E.F. (1996) Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation, 93, 1328-1330.
33. Rossi, E., Mondonico, P., Lombardi, A. & Preda, L. (1988) Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thrombosis Research, 52, 453-468.
34. Schneider, M., Boffa, M., Stewart, R., Rahman, M., Koschinsky, M. & Nesheim, M. (2002) Two naturally occurring variants of TAFI (Thr 325 and Ile 325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. Journal of Biological Chemistry, 277, 1021-1030.
35. Silveira, A., Schatteman, K., Goossens, F., Moor, E., Scharpe, S., Stromqvist, M., Hendriks, D. & Hamsten, A. (2000) Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thrombosis and Haemostasis, 84, 364-368.
36. Thogersen, A.M., Jansson, J.H., Boman, K., Nilson, T.K., Weinehall, L., Huhtasaari, F. & Hallmans, G. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation, 98, 2241-2247.
37. van Tilburg, N.H., Rosendaal, F.R. & Bertina, R.M. (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood, 95, 2855-2859.
38. Tregouet, D.A., Aubert, H., Henry, M., Morange, P., Visvikis, S., Juhan-Vague, I. & Tiret, L. (2001) Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Human Genetics, 109, 191-197.
39. Wang, W., Boffa, M.B., Bajzar, L., Walker, J.B. & Nesheim, M.E. (1998) A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. Journal of Biological Chemistry, 273, 27176-27181.